RxDoctor Payments Data

Maneesh Gaddam, MD

Pulmonary Disease · Hazard, KYNPI 1144604505

Payments from drug & device makers

$1,353in general payments, 2019–2025

Across 30 payments — averaging $45.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$969
  • Grifols USA, LLC$110
  • GSK$95
  • Philips North America LLC$56
  • Merck$37
  • Melinta Therapeutics, LLC$22
  • plus $64 from 4 others

What the payments were for

  • Travel & lodging$92468%
  • Food & beverage$42932%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,353 in reported general payments places this provider in the 25th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$49,923
Medicare patients
71
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Hazard

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →